A Case Report of Morbilliform Eruption after Vaccination of CoronaVac Vaccine
Keywords:
COVID-19, vaccine, sinovac, coronavacAbstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes the coronavirus disease 2019 (COVID-19) systemic viral syndrome responsible for an ongoing global pandemic. COVID-19 has led to high morbidity and mortality worldwide. The absence of immunity in the population could be susceptible to new waves of COVID-19 infection. The effective equipment to prevent this pandemic is the development of a potential vaccine against the disease. CoronaVac (Sinovac Life Sciences, Beijing, China) is an inactivated vaccine alternative against COVID-19, that has shown immunogenicity with vaccine-induced neutralizing antibodies to SARS-CoV-2. Nowadays, we have few reports about this vaccine, due to a short time of development. Currently, we report a case of 29-year-old Thai female with the developing of morbilliform rash on the face and chest 40 minutes following the first dose vaccination.
References
WHO. Coronavirus disease (COVID-19) situation report - 163. Geneva: World Health Organization, 2020 [Available from: https://www.who.int/ docs/default-source/coronaviruse/situation-reports/20200701-covid- 19-sitrep-163.pdf?sfvrsn=c202f05b_2.
Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R. High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2. Emerg Infect Dis. 2020;26(7):1470-7.
Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020;369(6499):77-81.
Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181-92.
Korman AM, Alikhan A, Kaffenberger BH. Viral exanthems: An update on laboratory testing of the adult patient. Journal of the American Academy of Dermatology. 2017;76(3):538-50.
Mawhirt SL, Frankel D, Diaz AM. Cutaneous Manifestations in Adult Patients with COVID-19 and Dermatologic Conditions Related to the COVID-19 Pandemic in Health Care Workers. Curr Allergy Asthma Rep. 2020;20(12):75.
Fattori A, Cribier B, Chenard MP, Mitcov M, Mayeur S, Weingertner N. Cutaneous manifestations in patients with coronavirus disease 2019: clinical and histological findings. Hum Pathol. 2021;107:39-45.
Gwynn ME, DeRemer DL, Saunders KM, Parikh J, Bollag RJ, Clemmons AB. Immune-mediated adverse events following influenza vaccine in cancer patients receiving immune checkpoint inhibitors. J Oncol Pharm Pract. 2020;26(3):647-54.
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-45.
Chu DK, Abrams EM, Golden DBK, Blumenthal KG, Wolfson AR, Stone CA, Jr., et al. Risk of Second Allergic Reaction to SARS-CoV-2 Vaccines: A Systematic Review and Meta-analysis. JAMA Intern Med. 2022;182(4):376-85.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Department of Medical Services, Ministry of Public Health
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
บทความที่ได้รับการตีพิมพ์เป็นลิขสิทธิ์ของกรมการแพทย์ กระทรวงสาธารณสุข
ข้อความและข้อคิดเห็นต่างๆ เป็นของผู้เขียนบทความ ไม่ใช่ความเห็นของกองบรรณาธิการหรือของวารสารกรมการแพทย์
